177 related articles for article (PubMed ID: 38256273)
41. Benefits of hepatitis C cure with antivirals: why test and treat?
Lledó G; Benítez-Gutiérrez L; Arias A; Requena S; Cuervas-Mons V; de Mendoza C
Future Microbiol; 2019 Mar; 14():425-435. PubMed ID: 30900911
[TBL] [Abstract][Full Text] [Related]
42. Changes in liver fibrosis in patients with chronic hepatitis C after successful direct-acting antiviral therapy.
Sadeghi A; Amiri R; Akbarpour E; Mirminachi B; Sharifi AH; Merat S
Int J Clin Pract; 2021 Jun; 75(6):e14145. PubMed ID: 33709413
[TBL] [Abstract][Full Text] [Related]
43. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
44. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
45. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent.
Bittermann T; Reddy KR
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2389-2397.e2. PubMed ID: 32971230
[TBL] [Abstract][Full Text] [Related]
46. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
47. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.
Tacke F; Klinker H; Boeker KHW; Merle U; Link R; Buggisch P; Hüppe D; Cornberg M; Sarrazin C; Wedemeyer H; Berg T; Mauss S;
Hepatol Commun; 2022 Sep; 6(9):2488-2495. PubMed ID: 35666055
[TBL] [Abstract][Full Text] [Related]
48. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
49. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
50. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
51. Mitochondrial DNA copy number in Hepatitis C virus-related chronic liver disease: impact of direct-acting antiviral therapy.
Elyamany A; Ghazala R; Fayed O; Hamed Y; El-Shendidi A
Sci Rep; 2023 Oct; 13(1):18330. PubMed ID: 37884543
[TBL] [Abstract][Full Text] [Related]
52. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
[TBL] [Abstract][Full Text] [Related]
53. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
54. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
Ippolito AM; Milella M; Messina V; Conti F; Cozzolongo R; Morisco F; Brancaccio G; Barone M; Santantonio T; Masetti C; Tundo P; Smedile A; Carretta V; Gatti P; Termite AP; Valvano MR; Bruno G; Fabrizio C; Andreone P; Zappimbulso M; Gaeta GB; Napoli N; Fontanella L; Lauletta G; Cuccorese G; Metrangolo A; Francavilla R; Ciracì E; Rizzo S; Andriulli A
Dig Liver Dis; 2017 Sep; 49(9):1022-1028. PubMed ID: 28487083
[TBL] [Abstract][Full Text] [Related]
55. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.
Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP
Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751
[TBL] [Abstract][Full Text] [Related]
56. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
Foster GR; Irving WL; Cheung MC; Walker AJ; Hudson BE; Verma S; McLauchlan J; Mutimer DJ; Brown A; Gelson WT; MacDonald DC; Agarwal K;
J Hepatol; 2016 Jun; 64(6):1224-31. PubMed ID: 26829205
[TBL] [Abstract][Full Text] [Related]
57. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
58. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study.
Ibáñez-Samaniego L; Rapado-Castro M; Cabrero L; Navarrete C; García-Mulas S; Ahumada A; Marquez L; Pérez MD; Rincon D; Bañares R; Garcia-Martinez R
Eur J Neurol; 2022 Feb; 29(2):400-412. PubMed ID: 34634159
[TBL] [Abstract][Full Text] [Related]
60. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
